
TWST Stock Forecast & Price Target
TWST Analyst Ratings
Bulls say
Twist Bioscience is well positioned because its silicon-based DNA synthesis platform lowers cost and increases throughput, creating a structural advantage in a market where scale and speed are critical, while its expanding footprint across synthetic biology, AI drug discovery, and NGS broadens growth drivers. Management’s FY27 guidance for $550M-$560M of revenue, ~$52.5%-53.0% gross margin, and positive adjusted EBITDA suggests a path to profitable growth even as the company invests about $75M in FY27 CapEx to expand capacity, automation, and software. The positive outlook is further supported by $100M of FY27 AI revenue, 20%+ NGS growth, commercial MRD launch, and 16 DNA writers of capacity equivalent to 50M+ pieces of DNA per day, all indicating strong demand and operating leverage.
Bears say
Twist Bioscience is facing a more cautious fundamental setup because FY27 guidance reset expectations, with management signaling at least $100M of AI revenue as a floor while implying a deceleration in ex-AI DSPS, which raises concern that near-term growth may not keep pace with optimism. Although F4Q26 revenue, gross margins, and adjusted EBITDA profitability were achieved on schedule, the company still appears dependent on significant quarterly beats to prove AI demand is additive rather than offsetting weakness in the legacy business. Added risk comes from slower NGS end-market growth, a sluggish biopharma R&D recovery, and possible competitive pressure, all of which could limit the sustainability of the beat-and-raise narrative.
This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Twist Bioscience Corp (TWST) Forecast
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares